Primary Human Chondrocytes Affected by Cigarette Smoke-Therapeutic Challenges.

Tao Chen, Sabrina Ehnert, Gauri Tendulkar, Sheng Zhu, Christian Arnscheidt, Romina H Aspera-Werz, Andreas K Nussler
Author Information
  1. Tao Chen: Siegfried Weller Research Institute, Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany. ORCID
  2. Sabrina Ehnert: Siegfried Weller Research Institute, Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany.
  3. Gauri Tendulkar: Siegfried Weller Research Institute, Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany.
  4. Sheng Zhu: Siegfried Weller Research Institute, Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany. ORCID
  5. Christian Arnscheidt: Siegfried Weller Research Institute, Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany.
  6. Romina H Aspera-Werz: Siegfried Weller Research Institute, Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany. ORCID
  7. Andreas K Nussler: Siegfried Weller Research Institute, Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany. ORCID

Abstract

Although several researchers have attested deleterious effects of smoking to the musculoskeletal system, the association between smoking and the onset of osteoarthritis (OA) remains unclear. Here, we investigate the effect of cigarette smoke extract (CSE) on primary human chondrocytes. The present study demonstrates that physiological concentrations of CSE (0.1%-10%) inhibit the viability, proliferation, and matrix formation of chondrocytes in a dose- and time-dependent manner. Significant amounts of free radicals were generated by 10% of CSE and led to cell death. A clinical dosage (4 mg/mL) of dexamethasone (Dex) showed toxic effects on chondrocytes, and the long-time treatment by lower doses (4-400 μg/mL) induced hypertrophic changes in the chondrocytes. To substitute Dex, diclofenac (Dic, 1 μg/mL) and acetaminophen (Ace, 10 μg/mL) were tested and did not worsen the metabolic activity of CSE-exposed chondrocytes. Hyaluronic acid (HA, 5 mg/mL) combined with Dic or Ace significantly inhibited the oxidative stress and enhanced the viability and matrix formation of CSE-exposed chondrocytes. This study shows for the first time that CSE mediates the disruption of cartilage through inducing cell death by increasing oxidative stress, and that this effect is fortified by Dex. The deleterious effects of CSE on chondrocytes could be reversed by treatment with HA combined with first-line analgesic/anti-inflammatory agents.

Keywords

References

  1. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32 [PMID: 20227026]
  2. Osteoarthritis Cartilage. 2005 Aug;13(8):688-96 [PMID: 15923130]
  3. Clin Pharmacol Ther. 1999 Jul;66(1):58-65 [PMID: 10430110]
  4. Arthritis Rheum. 2001 Jan;44(1):85-95 [PMID: 11212180]
  5. J Biol Chem. 2016 Mar 25;291(13):6641-54 [PMID: 26797130]
  6. Sci Rep. 2016 Oct 20;6:35544 [PMID: 27762336]
  7. J Proteomics. 2014 Mar 17;99:40-53 [PMID: 24480285]
  8. Exp Ther Med. 2018 May;15(5):4205-4212 [PMID: 29849772]
  9. J Pharm Sci. 2016 Jan;105(1):122-30 [PMID: 26852847]
  10. Int J Environ Res Public Health. 2009 Feb;6(2):445-62 [PMID: 19440393]
  11. Osteoarthritis Cartilage. 2007 Jan;15(1):27-34 [PMID: 16859932]
  12. DNA Cell Biol. 1996 Dec;15(12):1039-48 [PMID: 8985117]
  13. Open Access Maced J Med Sci. 2016 Dec 15;4(4):636-640 [PMID: 28028404]
  14. PLoS One. 2013 May 09;8(5):e62994 [PMID: 23671648]
  15. Osteoarthritis Cartilage. 2008 Feb;16(2):137-62 [PMID: 18279766]
  16. Arthritis Res Ther. 2009;11(5):R133 [PMID: 19723327]
  17. Rheumatology (Oxford). 2009 Oct;48(10):1227-31 [PMID: 19696062]
  18. Osteoarthritis Cartilage. 2010 Apr;18(4):476-99 [PMID: 20170770]
  19. Drugs. 1996 Oct;52(4):507-14 [PMID: 8891463]
  20. Osteoarthritis Cartilage. 2007 May;15(5):587-90 [PMID: 17291790]
  21. Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):1005-17 [PMID: 24836926]
  22. JCI Insight. 2018 Feb 8;3(3): [PMID: 29415878]
  23. Mol Cell Biochem. 2012 Jan;359(1-2):263-9 [PMID: 21853276]
  24. Apoptosis. 2010 May;15(5):631-8 [PMID: 20091349]
  25. Front Immunol. 2015 Nov 09;6:572 [PMID: 26617606]
  26. Lancet. 2019 Apr 27;393(10182):1745-1759 [PMID: 31034380]
  27. Bone Res. 2017 Jan 17;5:16044 [PMID: 28149655]
  28. Int J Mol Sci. 2019 Jun 14;20(12): [PMID: 31207955]
  29. J Orthop Res. 2001 Jul;19(4):703-11 [PMID: 11518282]
  30. Arch Toxicol. 2018 Apr;92(4):1525-1538 [PMID: 29264620]
  31. Bone Joint Res. 2019 Mar 2;8(2):41-48 [PMID: 30915209]
  32. Pain Res Manag. 2013 Sep-Oct;18(5):e63-7 [PMID: 24093120]
  33. BMC Vet Res. 2015 Dec 04;11:298 [PMID: 26637428]
  34. Drug Saf. 1990 May-Jun;5(3):205-11 [PMID: 2190596]
  35. J Bone Joint Surg Br. 2005 Aug;87(8):1143-9 [PMID: 16049255]
  36. BMC Musculoskelet Disord. 2017 Dec 21;18(1):542 [PMID: 29268731]
  37. Arthritis Res Ther. 2016 Jan 21;18:18 [PMID: 26792492]
  38. J Orthop Res. 2006 Jul;24(7):1472-9 [PMID: 16705735]
  39. Br J Clin Pharmacol. 2009 Jan;67(1):125-9 [PMID: 19133062]
  40. Osteoarthritis Cartilage. 2007 Oct;15(10):1217-20 [PMID: 17507255]
  41. Int J Mol Sci. 2016 Dec 20;17(12): [PMID: 27999417]
  42. Int J Mol Sci. 2018 Mar 27;19(4): [PMID: 29584629]
  43. Ann Rheum Dis. 2003 Dec;62(12):1145-55 [PMID: 14644851]
  44. Am J Vet Res. 2008 Aug;69(8):1013-21 [PMID: 18672964]
  45. Colloids Surf B Biointerfaces. 2013 Nov 1;111:289-96 [PMID: 23838195]
  46. Int J Mol Sci. 2015 Oct 30;16(11):26035-54 [PMID: 26528972]
  47. Aging Dis. 2018 Feb 1;9(1):143-150 [PMID: 29392089]
  48. Br J Pharmacol. 2000 Dec;131(7):1413-21 [PMID: 11090115]
  49. Rocz Panstw Zakl Hig. 2009;60(4):299-310 [PMID: 20361554]
  50. J Dev Biol. 2015 Dec;3(4):177-192 [PMID: 27347486]
  51. Biochem Biophys Res Commun. 2013 Nov 8;441(1):249-55 [PMID: 24141118]
  52. J R Soc Interface. 2012 Dec 7;9(77):3564-73 [PMID: 22809846]
  53. J Pharm Sci. 2016 Oct;105(10):3079-3087 [PMID: 27475785]
  54. J Orthop Res. 2017 Mar;35(3):406-411 [PMID: 27176565]
  55. Int J Mol Med. 2013 Dec;32(6):1311-8 [PMID: 24126970]
  56. Int J Mol Sci. 2019 Apr 06;20(7): [PMID: 30959917]
  57. Int J Environ Res Public Health. 2011 Feb;8(2):613-28 [PMID: 21556207]
  58. Osteoarthritis Cartilage. 2015 Apr;23(4):507-15 [PMID: 25447976]
  59. Arthritis Res Ther. 2007;9(3):R60 [PMID: 17596264]
  60. Crit Care Clin. 2012 Oct;28(4):499-516 [PMID: 22998987]
  61. J Orthop Res. 2014 Apr;32(4):566-72 [PMID: 24375646]
  62. J Biosci Bioeng. 2011 Oct;112(4):395-401 [PMID: 21778110]
  63. Orthop J Sports Med. 2015 Apr 27;3(5):2325967115581163 [PMID: 26674652]
  64. Osteoarthritis Cartilage. 2005 Oct;13(10):942-3 [PMID: 15908236]
  65. J Clin Med. 2019 Mar 24;8(3): [PMID: 30909629]
  66. BMC Musculoskelet Disord. 2017 Sep 6;18(1):387 [PMID: 28877688]
  67. Ann Rheum Dis. 2007 Jan;66(1):18-22 [PMID: 17158140]
  68. Oxid Med Cell Longev. 2018 Nov 6;2018:3172480 [PMID: 30533170]
  69. Mol Med Rep. 2014 Mar;9(3):923-7 [PMID: 24469312]
  70. Handb Exp Pharmacol. 2009;(192):29-60 [PMID: 19184645]
  71. Forensic Sci Int. 2001 Nov 1;122(2-3):107-23 [PMID: 11672964]
  72. Rheumatol Int. 2012 Nov;32(11):3669-73 [PMID: 21898067]

Grants

  1. 201808080147/China Scholarship Council

MeSH Term

Acetaminophen
Aged
Cell Proliferation
Cell Survival
Chondrocytes
Dexamethasone
Diclofenac
Dose-Response Relationship, Drug
Female
Humans
Hyaluronic Acid
Male
Middle Aged
Oxidative Stress
Primary Cell Culture
Smoke
Tobacco Products

Chemicals

Smoke
Diclofenac
Acetaminophen
Dexamethasone
Hyaluronic Acid

Word Cloud

Created with Highcharts 10.0.0chondrocytesCSEeffectsDexμg/mLdeleterioussmokingosteoarthritisOAeffectcigarettesmokestudyviabilitymatrixformationcelldeathmg/mLdexamethasonetreatmentdiclofenacDicacetaminophenAceCSE-exposedacidHAcombinedoxidativestresscartilageAlthoughseveralresearchersattestedmusculoskeletalsystemassociationonsetremainsunclearinvestigateextractprimaryhumanpresentdemonstratesphysiologicalconcentrations01%-10%inhibitproliferationdose-time-dependentmannerSignificantamountsfreeradicalsgenerated10%ledclinicaldosage4showedtoxiclong-timelowerdoses4-400inducedhypertrophicchangessubstitute110testedworsenmetabolicactivityHyaluronic5significantlyinhibitedenhancedshowsfirsttimemediatesdisruptioninducingincreasingfortifiedreversedfirst-lineanalgesic/anti-inflammatoryagentsPrimaryHumanChondrocytesAffectedCigaretteSmoke-TherapeuticChallengeschondrocytehyaluronicreactiveoxygenspeciesROS

Similar Articles

Cited By